Literature DB >> 24512727

MicroRNA-200c inhibits apoptosis in pituitary adenoma cells by targeting the PTEN/Akt signaling pathway.

Chuangxin Liao1, Wenli Chen, Xiang Fan, Xiaobing Jiang, Lubing Qiu, Chunhua Chen, Yonghong Zhu, Haijun Wang.   

Abstract

MicroRNAs (miRNAs) are important regulators that are involved in the development of different types of tumors. MicroRNA-200c (miR-200c) has been characterized as a tumor suppressor or oncogene in different cancers. However, the role of miR-200c in pituitary tumorigenesis remains unknown. We observed that miR-200c was overexpressed in pituitary adenoma cell lines. We transfected a miR-200c inhibitor into pituitary adenoma cells (MMQ cell line) to inhibit miR-200c expression and found that the percentage of apoptotic MMQ cells increased. Using bioinformatics analyses, we predicted that the tumor suppressor gene PTEN was targeted by miR-200c, and we confirmed the presence of a functional miR-200c binding site in the 3'-UTR of PTEN using luciferase reporter assays. We determined that the inhibition of miR-200c expression can upregulate PTEN expression and decrease the expression of phosphorylated Akt (p-Akt). Furthermore, the siRNA-mediated knockdown of PTEN abrogated the effect of inhibiting miR-200c expression. Taken together, these findings suggest that miR-200c regulates pituitary tumor formation through the PTEN/Akt signaling pathway. Therefore, we propose that the inhibition of miR-200c could have therapeutic potential in pituitary adenoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24512727     DOI: 10.3727/096504013X13832473329999

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  15 in total

1.  Kinases: a remote control in inflammasome activity.

Authors:  Alexander Czachor; Young Cho; Richard F Lockey; Narasaiah Kolliputi
Journal:  J Cell Commun Signal       Date:  2015-04-01       Impact factor: 5.782

2.  WWP1 as a potential tumor oncogene regulates PTEN-Akt signaling pathway in human gastric carcinoma.

Authors:  Li Zhang; Zongyin Wu; Zhao Ma; Hongtao Liu; Yahong Wu; Qinxian Zhang
Journal:  Tumour Biol       Date:  2014-10-09

3.  miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.

Authors:  Guangfeng Niu; Bin Li; Jianmin Sun; Li Sun
Journal:  Cell Prolif       Date:  2015-04-16       Impact factor: 6.831

4.  The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer.

Authors:  Korosh Heydari; Massoud Saidijam; Mohammad Reza Sharifi; Fatemeh Karimi Dermani; Sara Soleimani Asl; Nooshin Shabab; Rezvan Najafi
Journal:  Pathol Oncol Res       Date:  2017-04-14       Impact factor: 3.201

5.  MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.

Authors:  Kai Zhou; Tingrong Zhang; YanDong Fan; Guojia Du; Pengfei Wu; Dangmurenjiafu Geng
Journal:  Tumour Biol       Date:  2016-07-27

6.  Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma.

Authors:  Longmei Cai; Jinbang Li; Xiaona Zhang; Yaoyong Lu; Jianguo Wang; Xiaoming Lyu; Yuxiang Chen; Jinkun Liu; Hongbing Cai; Ying Wang; Xin Li
Journal:  Oncotarget       Date:  2015-04-10

Review 7.  MicroRNAs in Human Pituitary Adenomas.

Authors:  Xu-Hui Li; Elaine Lu Wang; Hai-Meng Zhou; Katsuhiko Yoshimoto; Zhi Rong Qian
Journal:  Int J Endocrinol       Date:  2014-12-08       Impact factor: 3.257

Review 8.  MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma.

Authors:  Jianing Yan; Shibo Ying; Xiujun Cai
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

Review 9.  The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy.

Authors:  Brock Humphries; Chengfeng Yang
Journal:  Oncotarget       Date:  2015-03-30

10.  MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma.

Authors:  Peng Qiu; Tong-Jiang Xu; Xiang-Dong Lu; Wei Yang; Yu-Bao Zhang; Guang-Ming Xu
Journal:  Oncol Lett       Date:  2017-11-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.